Goal-Directed Resuscitation for Patients with Early Septic Shock
Source: View publication →
In this large, multicenter randomized controlled trial, early goal-directed therapy (EGDT) for patients presenting to the emergency department with early septic shock did not reduce all-cause mortality at 90 days compared with standard care.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ARISE trial, alongside the ProCESS and ProMISe trials, demonstrated that a rigid, protocolized bundle of early goal-directed therapy is not superior to standard resuscitative care for early septic shock when standard care already involves early recognition, prompt antibiotics, and appropriate fluid resuscitation, essentially shifting the focus toward a more generalized, early intervention strategy.
Historical Context
The study was designed to rigorously test the landmark 2001 single-center study by Rivers et al., which reported a substantial mortality benefit with EGDT. Given the widespread, heterogeneous adoption of the Rivers protocol, ARISE was initiated to provide high-level evidence regarding its effectiveness in a modern, multicenter, international setting.
Guided Discussion
High-yield insights from every perspective
The original Early Goal-Directed Therapy (EGDT) protocol emphasized achieving specific targets for Central Venous Pressure (CVP), Mean Arterial Pressure (MAP), and Superior Vena Cava Oxygen Saturation (ScvO2). From a physiological perspective, why was ScvO2 considered a critical marker of the balance between oxygen delivery and consumption in early sepsis?
Key Response
ScvO2 reflects the amount of oxygen remaining in the blood after tissues have extracted what they need. In early sepsis, tissue oxygen demand often exceeds delivery (DO2), leading to increased oxygen extraction and a drop in ScvO2. The ARISE trial suggests that while the physiology remains valid, modern standard care (early fluids and antibiotics) may normalize this balance sufficiently without the need for invasive ScvO2 monitoring.
In the ARISE trial, the 'usual care' group had a 90-day mortality rate of 18.8%, which was nearly identical to the EGDT group. Given that 'usual care' clinicians were not required to follow a specific protocol, what are the core elements of sepsis management that have likely become 'standard' since the original 2001 Rivers trial, explaining this lack of difference?
Key Response
The 'standard of care' evolved significantly between 2001 and the ARISE trial (published 2014). Residents should recognize that early recognition, rapid administration of intravenous fluids (average 2.5L prior to randomization in ARISE), and early initiation of appropriate antibiotics are now the cornerstones of therapy, making the incremental benefit of invasive catheters and blood transfusions (specified in EGDT) negligible for the majority of patients.
The ARISE trial, along with ProCESS and ProMISe, formed the PRISM meta-analysis. When interpreting the 'null' results of ARISE, how should a clinician reconcile these findings with the potential existence of a 'high-risk' subgroup (e.g., those with profound lactate elevation or refractory hypotension) who might still benefit from the intensive monitoring components of the original EGDT protocol?
Key Response
Fellows must understand the concept of treatment effect heterogeneity. While ARISE showed no benefit in a broad population with a mortality of ~18%, the original Rivers trial had a mortality of ~46%. The lack of benefit in ARISE may be due to the 'ceiling effect' of improved baseline care or the inclusion of lower-acuity patients. For the 'sickest of the sick,' the metabolic information provided by ScvO2 or lactate clearance may still guide vasopressor or inotropic titration in a way that 'usual care' cannot.
If the ARISE trial proves that the resource-intensive requirements of EGDT (central venous catheterization, continuous ScvO2 monitoring, and strict algorithmic pacing) do not improve outcomes, how should this change the allocation of nursing and physician resources in a busy Emergency Department during the first six hours of sepsis resuscitation?
Key Response
The attending perspective focuses on systems and teaching. ARISE allows for 'de-implementation' of invasive, time-consuming procedures that do not add value, allowing the team to focus on high-yield interventions: source control, timely antibiotics, and dynamic assessment of fluid responsiveness (like passive leg raises or ultrasound) rather than static pressure targets like CVP.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ARISE trial reported a 90-day mortality endpoint. From a trial design perspective, discuss the implications of using a 90-day mortality rate versus a 28-day mortality rate in septic shock, particularly regarding the potential for 'competing risks' and the impact of post-discharge care on the study's power to detect a treatment effect tied specifically to ED-based interventions.
Key Response
90-day mortality captures late deaths that may be due to the sequelae of sepsis, but it also introduces noise from comorbidities and post-hospital care. A PhD-level analysis would critique whether an intervention lasting only 6 hours in the ED can realistically be expected to exert a statistically significant signal over a 90-day window, or if a more proximal endpoint (like organ-failure-free days) would have been more sensitive to the physiological impact of the protocol.
As a reviewer, how would you address the 'Hawthorne Effect' in the ARISE trial, specifically the concern that the clinicians providing 'usual care' were highly trained experts aware of the EGDT principles, thereby potentially 'contaminating' the control arm and biasing the results toward the null?
Key Response
This is a classic threat to internal validity in non-blinded behavioral or procedural trials. Editors look for how the authors defined 'usual care' and whether there were process measures (like volume of fluid or time to antibiotics) that showed the control group was actually performing 'EGDT-lite.' If the control group is too good, the trial becomes a test of 'Protocolized vs. Non-Protocolized High-Quality Care' rather than 'EGDT vs. Standard Practice.'
The Surviving Sepsis Campaign (SSC) guidelines significantly shifted their recommendations following the ARISE, ProCESS, and ProMISe trials. Should current guidelines completely abandon the 6-hour bundle targets for CVP and ScvO2, or should they be maintained as 'weak recommendations' for specific clinical scenarios?
Key Response
The SSC 2016 and 2021 updates moved away from CVP/ScvO2 as mandatory targets. Guideline committees must balance the high-quality evidence from ARISE (which suggests no benefit) against the need to provide clinicians with alternative markers. The committee's rationale for moving toward dynamic measures (like skin re-capillary time or SV variation) is directly supported by the lack of superiority shown by the invasive targets in ARISE.
Clinical Landscape
Noteworthy Related Trials
Rivers Early Goal-Directed Therapy
Tested
Early goal-directed therapy (EGDT) protocol
Population
Patients presenting to the ED with severe sepsis or septic shock
Comparator
Standard care
Endpoint
In-hospital mortality
ProCESS Trial
Tested
Protocol-based EGDT versus protocol-based standard therapy
Population
Patients with septic shock in the emergency department
Comparator
Usual care
Endpoint
60-day in-hospital mortality
ProMISe Trial
Tested
Early goal-directed therapy (EGDT)
Population
Patients with early septic shock in the United Kingdom
Comparator
Standard care
Endpoint
All-cause mortality at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis